stockmarketproxy
/
MRKNYSESEC EDGAREDGAR

Merck & Co., Inc.

Pharmaceutical Preparations·RAHWAY, NJ·FY end 12/31·CIK 310158
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$65.0B$64.2B$60.1B$59.3B$48.7B
Gross Profit——————
Operating Income——————
Net Income$18.3B$17.1B$365.0M$14.5B$13.0B
Operating CF$16.5B$21.5B———
Capex$4.1B$3.4B$3.9B——
Free Cash Flow$12.4B$18.1B———
Buybacks$5.1B$1.3B$1.3B$0$840.0M
Dividends$8.2B$7.8B$7.4B$7.0B$6.6B
Gross Margin——————
Operating Margin——————
Net Margin28.1%26.7%0.6%24.5%26.8%
FCF Margin19.0%28.2%———
R&D / Revenue24.3%28.0%50.8%22.9%25.1%
Effective Tax13.3%14.1%80.0%11.7%11.0%
Debt / Equity0.890.740.900.630.80
Buybacks / FCF41.1%7.2%———

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
MRK
191:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
MRK
$21M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
MRK
28.1%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%